FDA updates rilpivirine label for use during pregnancy
Simon Collins, HIV i-Base
On 31 October 2018, the US FDA approved changes to the label for fixed dose combinations (FDC) containing rilpivirine: Odefsey (RPV/FTC/TAF) and Eviplera/Complera (RPV/FTC/TDF).
For pregnant patients who are already on an RPV-based FDC prior to pregnancy and are virologically suppressed (HIV-1 RNA less than 50 copies/mL), one tablet, once daily may be continued.
Lower exposures of rilpivirine were observed during pregnancy, therefore viral load should be monitored closely.
A similar recommendation was recently made for rilpivirine (RPV) (trade name Edurant) as a single ARV.
FDA list serve update (31 October 2018)